New Study Identifies 36 High-Impact Genes Linking OCD, Tics, and Autism

Key points

• A team led by Rutgers University researchers identified 36 high-confidence risk genes for OCD and chronic tic disorders, a tenfold increase from the previous four known genes.
• The study analyzed exome data from nearly 4,000 individuals, including 2,400 parent-child trios and 1,500 singletons, using data collected over the past 20 years.
• Thirty of the 36 identified genes are associated with both OCD and CTD, confirming significant genetic overlap between the two conditions, which frequently co-occur.
• The risk genes are linked to other neurodevelopmental disorders, including autism spectrum disorder, developmental delays, and schizophrenia, but not to congenital heart disease.
• The genes show high expression in the cortex, striatum, thalamus, and cerebellum, particularly in telencephalic projecting excitatory neurons, affecting impulse control and movement.
• The identified genes carry large effects, with an average risk increase of 57-fold and up to 210-fold at the extreme end, providing new targets for pharmaceutical development.

Background

Previous research had identified only four high-confidence genes for OCD and chronic tic disorders, limiting therapeutic development opportunities. A September 2026 archive article noted that a large whole-exome sequencing study of 3,964 individuals found enrichment of de novo and rare damaging coding variants, identifying 36 high-confidence risk genes using the TADA framework. This aligns with the current findings, which emphasize the expansion of the genetic landscape and cross-disorder overlap. Earlier coverage also highlighted the social and psychological impacts of tic disorders, such as the 2021 TikTok-driven mass illness among teens and the challenges of disclosure in academic settings, underscoring the need for better understanding and treatment of these conditions.

Why it matters

This study provides a detailed genetic blueprint for OCD and chronic tic disorders, offering 30 new targets for drug development. By identifying genes with large effects and linking them to other neurodevelopmental conditions, the research opens up possibilities for tailored therapies based on specific genetic or brain pathways. The findings also highlight the importance of long-term data collection and family participation in genetic research, enabling modern sequencing technologies to unlock valuable insights from samples collected decades ago.

What to watch

Researchers aim to design better therapies with tailored treatments based on specific genetic or brain pathways for diverse individuals with neurodevelopmental disorders. The identification of 36 high-impact risk genes, compared to the previous four, significantly expands the opportunities for the pharmaceutical industry to develop new drugs. Future studies may focus on the complex interactions between these genes and neural pathways, particularly in the cortico-striato-thalamo-cortical circuit, to further understand the biological mechanisms underlying these conditions.